Actelion Pharmaceuticals Ltd.’s three-year-old strategy of diversifying its business away from top-selling Tracleer (bosentan) appears to be maturing in the nick of time, with the ramp-up in sales of its latest PAH therapy Opsumit (macitentan) likely to replace company revenues lost through emerging generic competition to Tracleer and several other products including inhaled therapy Ventavis (iloprost) and the oral Gaucher disease therapy Zavesca (miglustat).
The U.S
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?